RBC Europe’s Lisata Therapeutics LSTA Stock Holding History

RBC Europe’s Portfolio LSTA Stock Details LSTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	-$12	–	913
2021 Q3	$12	Hold	1	–	–	﹤0.01%	1232
2021 Q2	$16	Hold	1	–	–	﹤0.01%	1225
2021 Q1	$19	Hold	1	–	–	﹤0.01%	1173
2020 Q4	$14	Hold	1	–	–	﹤0.01%	1145
2020 Q3	$18	Hold	1	–	–	﹤0.01%	1093
2020 Q2	$18	Hold	1	–	–	﹤0.01%	1059
2020 Q1	$18	Hold	1	–	–	﹤0.01%	1035
2019 Q4	$25	Hold	1	–	–	﹤0.01%	1043
2019 Q3	$26	Hold	1	–	–	﹤0.01%	1046
2019 Q2	$23	Hold	1	–	–	﹤0.01%	1060
2019 Q1	$36	Hold	1	–	–	﹤0.01%	1071
2018 Q4	$36	Hold	1	–	–	﹤0.01%	1082
2018 Q3	$59	Hold	1	–	–	﹤0.01%	1118
2018 Q2	$65	Hold	1	–	–	﹤0.01%	1128
2018 Q1	$58	Hold	1	–	–	﹤0.01%	1113
2017 Q4	$35	Hold	1	–	–	﹤0.01%	1128
2017 Q3	$36	Buy	+1	New	+$61	﹤0.01%	1130

Other funds holding LSTA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

RBC Europe's LSTA Position: Q4 2021 in Review

RBC Europe sold out of Lisata Therapeutics (LSTA) in Q4 2021, closing a stake of 1 share — an estimated $12 sold.

RBC Europe first reported a position in LSTA in Q3 2017 and held it in 17 quarters. The position peaked at $65 in Q2 2018. 34 funds tracked by Wall St. Rank hold LSTA as of Q4 2021.

RBC Europe reported no remaining Lisata Therapeutics position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 1 Lisata Therapeutics share in Q4 2021, an estimated $12.
RBC Europe first reported a position in Lisata Therapeutics in Q3 2017 and held it in 17 quarters.
RBC Europe's Lisata Therapeutics position peaked at $65 in Q2 2018.
34 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.